Department of Cardiovascular Sciences, Centre for Molecular and Vascular Biology, KU Leuven, Belgium.
Department of Cardiology, CARIM School for Cardiovascular Diseases Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands.
Sci Rep. 2018 Aug 9;8(1):11922. doi: 10.1038/s41598-018-29812-w.
Diabetic retinopathy (DR) is one of the major complications of diabetes, which eventually leads to blindness. Up to date, no animal model has yet shown all the co-morbidities often observed in DR patients. Here, we investigated whether obese 42 weeks old ZSF1 rat, which spontaneously develops diabetes, hypertension and obesity, would be a suitable model to study DR. Although arteriolar tortuosity increased in retinas from obese as compared to lean (hypertensive only) ZSF1 rats, vascular density pericyte coverage, microglia number, vascular morphology and retinal thickness were not affected by diabetes. These results show that, despite high glucose levels, obese ZSF1 rats did not develop DR. Such observations prompted us to investigate whether the expression of genes, possibly able to contain DR development, was affected. Accordingly, mRNA sequencing analysis showed that genes (i.e. Npy and crystallins), known to have a protective role, were upregulated in retinas from obese ZSF1 rats. Lack of retina damage, despite obesity, hypertension and diabetes, makes the 42 weeks of age ZSF1 rats a suitable animal model to identify genes with a protective function in DR. Further characterisation of the identified genes and downstream pathways could provide more therapeutic targets for the treat DR.
糖尿病性视网膜病变(DR)是糖尿病的主要并发症之一,最终可导致失明。迄今为止,还没有一种动物模型能显示出 DR 患者常出现的所有合并症。在这里,我们研究了自发性发生糖尿病、高血压和肥胖的 42 周龄 ZSF1 大鼠是否可以作为研究 DR 的合适模型。虽然与瘦(仅高血压)ZSF1 大鼠相比,肥胖大鼠的视网膜小动脉出现了扭曲,但血管密度、周细胞覆盖率、小胶质细胞数量、血管形态和视网膜厚度不受糖尿病影响。这些结果表明,尽管血糖水平较高,但肥胖的 ZSF1 大鼠并未发展为 DR。这些观察结果促使我们研究可能有助于控制 DR 发展的基因表达是否受到影响。因此,mRNA 测序分析表明,已知具有保护作用的基因(即 Npy 和晶体蛋白)在肥胖的 ZSF1 大鼠视网膜中上调。尽管肥胖、高血压和糖尿病,但视网膜没有损伤,这使得 42 周龄的 ZSF1 大鼠成为一种合适的动物模型,可以鉴定出 DR 中具有保护作用的基因。对鉴定出的基因和下游途径的进一步研究可为治疗 DR 提供更多的治疗靶点。